Meyka Pro banner
Codexis, Inc.

Codexis, Inc. Fundamental Analysis (NASDAQ: CDXS)

CDXSNASDAQ
HealthcareBiotechnology
$1.67
$0.07(4.37%)
U.S. Market opens in 10h 26m

Codexis, Inc. Fundamental Analysis (NASDAQ: CDXS)

Codexis, Inc. (NASDAQ: CDXS) shows moderate financial fundamentals with a PE ratio of -4.97, profit margin of -39.55%, and ROE of -74.36%. The company generates $0.1B in annual revenue with strong year-over-year growth of 18.61%.

Key Strengths

Cash Position38.17%
PEG Ratio-0.05
Current Ratio3.06

Areas of Concern

ROE-74.36%
Operating Margin-31.23%
We analyze CDXS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -75.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-75.6/100

We analyze CDXS's fundamental strength across five key dimensions:

Efficiency Score

Weak

CDXS struggles to generate sufficient returns from assets.

ROA > 10%
-25.59%

Valuation Score

Excellent

CDXS trades at attractive valuation levels.

PE < 25
-4.97
PEG Ratio < 2
-0.05

Growth Score

Excellent

CDXS delivers strong and consistent growth momentum.

Revenue Growth > 5%
18.61%
EPS Growth > 10%
43.82%

Financial Health Score

Moderate

CDXS shows balanced financial health with some risks.

Debt/Equity < 1
2.20
Current Ratio > 1
3.06

Profitability Score

Weak

CDXS struggles to sustain strong margins.

ROE > 15%
-7436.06%
Net Margin ≥ 15%
-39.55%
Positive Free Cash Flow
No

Key Financial Metrics

Is CDXS Expensive or Cheap?

P/E Ratio

CDXS trades at -4.97 times earnings. This suggests potential undervaluation.

-4.97

PEG Ratio

When adjusting for growth, CDXS's PEG of -0.05 indicates potential undervaluation.

-0.05

Price to Book

The market values Codexis, Inc. at 4.61 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.61

EV/EBITDA

Enterprise value stands at -6.21 times EBITDA. This is generally considered low.

-6.21

How Well Does CDXS Make Money?

Net Profit Margin

For every $100 in sales, Codexis, Inc. keeps $-39.55 as profit after all expenses.

-39.55%

Operating Margin

Core operations generate -31.23 in profit for every $100 in revenue, before interest and taxes.

-31.23%

ROE

Management delivers $-74.36 in profit for every $100 of shareholder equity.

-74.36%

ROA

Codexis, Inc. generates $-25.59 in profit for every $100 in assets, demonstrating efficient asset deployment.

-25.59%

Following the Money - Real Cash Generation

Operating Cash Flow

Codexis, Inc. generates limited operating cash flow of $-12.29M, signaling weaker underlying cash strength.

$-12.29M

Free Cash Flow

Codexis, Inc. generates weak or negative free cash flow of $-14.39M, restricting financial flexibility.

$-14.39M

FCF Per Share

Each share generates $-0.13 in free cash annually.

$-0.13

FCF Yield

CDXS converts -6.74% of its market value into free cash.

-6.74%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.97

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.05

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.61

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.31

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.20

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.06

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.74

vs 25 benchmark

ROA

Return on assets percentage

-0.26

vs 25 benchmark

ROCE

Return on capital employed

-0.25

vs 25 benchmark

How CDXS Stacks Against Its Sector Peers

MetricCDXS ValueSector AveragePerformance
P/E Ratio-4.9730.97 Better (Cheaper)
ROE-74.36%515.00% Weak
Net Margin-39.55%30197.00% Weak
Debt/Equity2.200.53 Weak (High Leverage)
Current Ratio3.065.71 Strong Liquidity
ROA-25.59%-16.00% (disorted) Weak

CDXS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Codexis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-30.57%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-24.76%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

19.83%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ